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Introduction
Parkinson’s disease (PD) is the second most common progres-
sive neurodegenerative disorder. The neurological lesions are 
frequently accompanied by cytoplasmic inclusion bodies, termed 
Lewy bodies, which contain ubiquitin-positive protein aggre-
gates (McNaught et al., 2002). The prevalence of Lewy bodies 
has led to a central proposal that aberrant accumulation of pro-
tein aggregate is a key contributing factor to the development of 
Parkinsonism. In addition to protein aggregates, mitochondrial 
dysfunction has emerged as another prominent pathological 
feature associated with PD. It has been long recognized that 
inhibitors of mitochondrial complex I can elicit Parkinsonian 
syndrome in human and rodent models. Indeed, complex I 
deficiency has been observed in PD patients (for review see 
Abou-Sleiman et al., 2006). The commonality of mitochondrial 
defects and protein aggregates in PD suggest that the accumulation 
of these toxic entities might be mechanistically linked. Uncover-
ing this potential link could provide an important clue to the 
fundamental defects underlying PD.
Mutations in parkin (PARK2) account for almost 50% of 
familial autosomal recessive juvenile PD (AR-JP; Lücking et al., 
2000). The prevalence of parkin mutations in AR-JP sug-
gests a dominant role for parkin in suppressing Parkinsonism 
(Abou-Sleiman et al., 2006). Parkin encodes for a RING domain–
containing ubiquitin E3 ligase (Shimura et al., 2000; Zhang 
et al., 2000). Several disease-associated parkin mutants are 
deficient in E3 ligase activity, suggesting that parkin sup-
presses Parkinsonism by promoting ubiquitination. In the cell-
based model, parkin can poly-ubiquitinate mutant DJ-1 and 
-synuclein–associated synphilin, which are both involved in 
PD (Chung et al., 2001; Lim et al., 2005; Olzmann et al., 2007). 
M
utations  in  parkin,  a  ubiquitin  ligase,  cause 
early-onset familial Parkinson’s disease (AR-JP). 
How parkin suppresses Parkinsonism remains 
unknown. Parkin was recently shown to promote the clear-
ance  of  impaired  mitochondria  by  autophagy,  termed 
mitophagy. Here, we show that parkin promotes mitophagy 
by catalyzing mitochondrial ubiquitination, which in turn 
recruits ubiquitin-binding autophagic components, HDAC6 
and p62, leading to mitochondrial clearance. During the 
process, juxtanuclear mitochondrial aggregates resem-
bling  a  protein  aggregate-induced  aggresome  are   
formed. The formation of these “mito-aggresome” structures   
requires  microtubule  motor-dependent  transport  and  is 
essential  for  efficient  mitophagy.  Importantly,  we  show   
that AR-JP–causing parkin mutations are defective in sup-
porting mitophagy due to distinct defects at recognition, 
transportation, or ubiquitination of impaired mitochon-
dria, thereby implicating mitophagy defects in the devel-
opment of Parkinsonism. Our results show that impaired 
mitochondria and protein aggregates are processed by 
common ubiquitin-selective autophagy machinery connected 
to the aggresomal pathway, thus identifying a mecha-
nistic basis for the prevalence of these toxic entities in 
Parkinson’s disease.
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Results and discussion
Disease-associated parkin mutants are 
deficient in promoting mitophagy
Overexpressed parkin was recently reported to promote the 
clearance of depolarized mitochondria by mitophagy (Narendra 
et al., 2008). We found that SH-SYY5 neuroblastoma cells, 
which express high levels of endogenous parkin, indeed lost 
mitochondria in response to the mitochondrial uncoupler, car-
bonyl cyanide m-chlorophenylhydrazone (CCCP) (Fig. S1). 
Thus, endogenous parkin can support mitophagy. To investi-
gate whether the mitophagy activity is linked to development 
of PD, we determined if parkin mutations associated with 
familial AR-JP are defective in supporting mitophagy. We 
chose to study representative parkin mutants R42P, R275W, 
A240R, and T415N that affect three conserved domains in 
parkin: ubiquitin-like (UBL) domain, RING-1, and RING-2 
domains. We expressed wild-type or disease-associated par-
kin  mutants  in  mouse  embryo  fibroblasts  (MEFs),  which 
have undetectable levels of parkin protein, and assessed their 
ability to clear impaired mitochondria induced by CCCP. As 
expected, in the absence of CCCP, wild-type and parkin mu-
tants were largely cytosolic, did not colocalize with mito-
chondria, and had little effect on mitochondrial abundance or 
morphology (Fig. S2). Upon CCCP treatment, a prominent 
loss of mitochondria was observed in a significant percent-
age of cells expressing wild-type parkin (Fig. 1, A and B).   
In stark contrast, mitochondria were retained in cells express-
ing disease-associated parkin mutants after CCCP treatment 
(Fig. 1, A and B). The defect in mitophagy was further con-
firmed by immunoblotting analysis for the loss of mitochon-
drial  markers  (Fig.  1  C).  Unlike  wild-type  parkin,  whose 
expression resulted in significant loss of mitochondrial cyto-
chrome c upon CCCP treatment, none of the disease-associated 
parkin mutants showed such an activity. We conclude that 
the disease-associated parkin mutations are defective in sup-
porting mitophagy.
Disease-causing parkin mutants arrest 
mitophagy at distinct steps
Although every parkin mutant tested in our assay was defec-
tive in clearing impaired mitochondria, their phenotypes were 
distinct. Although wild-type parkin prominently colocalized 
with mitochondria upon CCCP treatment (see below), UBL 
domain  mutant  parkin-R42P  did  not,  suggesting  that  the   
UBL domain is involved in recruitment of parkin to damaged 
mitochondria (Fig. 1 A). We found that A240R and T415N 
mutants, which are deficient in the ubiquitin E3 ligase activity 
(Zhang et al., 2000; Sriram et al., 2005), prominently associ-
ated with depolarized mitochondria and, remarkably, induced 
the formation of large mitochondrial aggregates in the peri-
nuclear region (Fig. 1 A). In contrast, parkin R275W mutant, 
while apparently localized to mitochondria, did not induce 
the formation of perinuclear mitochondrial aggregates (Fig. 1 A). 
These  results  show  that  all  PD-associated  parkin  mutants 
tested are defective in supporting mitophagy but with dis-
tinct phenotypes.
Interestingly, parkin-mediated ubiquitination of synphilin or 
DJ-1 does not lead to rapid degradation by the proteasome 
(Lim et al., 2005). For DJ-1, ubiquitination recruits a ubiquitin-
binding protein deacetylase, HDAC6, which facilitates the 
transport of DJ-1 to the microtubule-organizing center, form-
ing the inclusion body, aggresome (Olzmann et al., 2007). 
Evidence indicates that HDAC6-dependent aggresomal path-
way concentrates toxic protein aggregates for subsequent clear-
ance by autophagy (Kawaguchi et al., 2003; Iwata et al., 2005; 
Pandey et al., 2007; Lee et al., 2010). Aggresomes share many 
features with Lewy bodies, suggesting that active concentra-
tion of protein aggregate might be a neuroprotective mecha-
nism in PD patients (McNaught et al., 2002). Accordingly, 
parkin might protect neurons by promoting the clearance of 
toxic protein aggregates, although there is not yet definitive 
experimental support to this proposition.
Characterization of parkin mutant animal models has 
revealed prominent mitochondrial defects (for review see Abou-
Sleiman et al., 2006). How parkin affects mitochondrial function-
ality remains poorly understood. Recently, parkin was found to 
associate with functionally impaired and depolarized mitochon-
dria. Remarkably, parkin-marked mitochondria were subse-
quently cleared by autophagy, which sequesters and delivers 
damaged mitochondria via autophagosomes to lysosomes for 
elimination (Narendra et al., 2008). In principle, this mitophagy 
activity could protect neurons by eliminating dysfunctional mito-
chondria, which could produce toxic reactive oxygen species 
that damage neurons. How parkin promotes the clearance of 
impaired mitochondria and whether mitophagy is important in 
suppressing Parkinsonism are not known.
Historically, autophagy has been principally characterized 
as a nonselective degradative pathway activated by starvation. 
However, independent of nutrient status, autophagy has emerged 
as main quality control machinery that selectively disposes 
protein aggregates and damaged organelles (for review see 
Mizushima et al., 2008). This so-called quality control (QC) 
autophagy is fundamentally different from starvation-induced 
autophagy in its unique involvement of ubiquitinated substrates 
and the ubiquitin-binding HDAC6 and p62 (Lee et al., 2010). 
In QC autophagy, it was proposed that HDAC6 recruits a cor-
tactin-dependent actin-remodeling machinery to ubiquitinated 
protein aggregates, where the assembly of F-actin facilitates 
autophagosome–lysosome fusion and clearance of autophagic 
substrates (Lee et al., 2010). Whether mitophagy operates by a 
similar molecular mechanism is a fundamental question that re-
mains to be answered.
In this report, we provide evidence that parkin induces 
mitophagy by promoting the ubiquitination of dysfunctional 
mitochondria. The parkin-mediated ubiquitination serves to 
recruit ubiquitin-binding deacetylase HDAC6 and p62, which 
assemble  autophagy  machinery  that  clears  impaired  mito-
chondria. We also found that parkin-dependent mitophagy re-
quires the formation of juxtanuclear mitochondrial inclusion 
bodies that resemble the aggresome. Importantly, we showed 
that several disease-causing parkin mutants are defective in 
mitophagy, thereby supporting a critical role for mitophagy in 
suppressing Parkinsonism.673 Disease-causing mutations in Parkin impair mitophagy • Lee et al.
Microtubule dynein motors are required for 
parkin to induce aggregation and clearance 
of impaired mitochondria
The perinuclear mitochondrial aggregates are reminiscent of 
the aggresome, an inclusion body where protein aggregates 
are concentrated by the microtubule dynein motor (Johnston 
et  al.,  2002).  To  determine  if  impaired  mitochondria  are 
similarly concentrated to the perinuclear region by dynein-
dependent transport, parkin-expressing MEFs were treated 
with  a  microtubule-destabilizing  reagent,  nocodazole.  As 
shown in Fig. 2 A (bottom) and 2 B, nocodazole signifi-
cantly inhibited the formation of juxtanuclear mitochondrial 
aggregates  but  did  not  affect  parkin  localization  to  mito-
chondria. Further, overexpression of dynamitin, which inhibits   
dynein motor activity, also suppressed mitochondrial aggregate 
The distinct mitochondrial phenotypes caused by differ-
ent parkin mutations suggest that the clearance of impaired 
mitochondria involves multiple discrete steps. We further in-
vestigated the formation of perinuclear mitochondrial aggre-
gates, as they show some features of aggresomes. We first 
determined if mitochondrial aggregate formation is part of 
mitophagy induced by wild-type parkin and CCCP. To this 
end, we assessed mitochondrial status at different time points 
after CCCP treatment. As shown in Fig. 2 A, although mito-
chondria were largely cleared after 24 h treatment, prominent 
perinuclear-localized mitochondrial aggregates were observed   
in the majority of parkin-expressing cells (80%) at 8 h (Fig. 2).   
This result suggests that formation of perinuclear mitochondrial 
aggregates is an intermediate step for parkin-CCCP–induced 
mitophagy (Fig. 2).
Figure 1.  Disease-associated Parkin mutations are defective in mitophagy. (A) MEFs were transfected with GFP-tagged wild-type (WT) or mutant Parkin 
expression plasmid followed by an 18-h treatment of CCCP. Cells are immunostained with a Tom20 antibody to visualize mitochondria (red). GFP-parkin– 
transfected cells are marked by dotted lines. Arrows indicate parkin-positive mitochondria or mitochondrial aggregates. Bar, 10 µm. (B) The average per-
centages of mitochondria-free cells from three independent experiments from A are presented with standard deviation as error bar. **, P < 0.01 (C) MEFs 
were transfected and treated with CCCP as described in A, followed by an immunoblotting analysis with antibodies for cytochrome c, actin, and parkin. 
Note that levels of parkin R275W and R42P mutant were lower, as previously reported (Wang et al., 2005).JCB • VOLUME 189 • NUMBER 4 • 2010   674
species were detected in purified mitochondria after CCCP 
treatment (Fig. 3 C). In stark contrast, the majority of mito-
chondrial aggregates in parkin E3 ligase-deficient A240R- 
and T415N-expressing cells lacked ubiquitin signals (Fig. 3, 
A  and  B).  Immunoblotting  of  purified  mitochondria  from 
parkin-A240R and T415N-expressing cells confirmed a re-
duction in ubiquitination (Fig. 3 D). These results indicate 
that parkin induces ubiquitination in impaired mitochondria 
and this ubiquitination is required for efficient clearance of 
impaired mitochondria.
Mitochondrial ubiquitination recruits 
ubiquitin-binding p62 and HDAC6
We have recently shown that ubiquitin modification in protein 
aggregates serves to recruit two key regulatory components of 
autophagy machinery, p62 and HDAC6, both with intrinsic 
ubiquitin-binding activity. p62 binds the key autophagosome 
component LC3, whereas HDAC6 activates an actin-remodeling 
machinery that promotes autophagosome–lysosome fusion, 
thereby enhancing autophagy activity (Pankiv et al., 2007; Lee   
formation  (Fig.  S3 A).  Importantly,  nocodazole  treatment 
significantly inhibited parkin-CCCP–induced mitochondrial 
clearance (Fig. 2 B), indicating that dynein motor–dependent 
aggregate formation is required for efficient clearance of im-
paired mitochondria.
Parkin induces ubiquitination of  
impaired mitochondria
We next determined how parkin promotes the clearance of 
mitochondria by autophagy. We noticed that although parkin 
A240R and T415N mutants induced perinuclear mitochondrial 
aggregate formation, these mitochondria are not cleared (Fig. 1). 
As A240R and T415N parkin mutants share a common bio-
chemical defect in E3 ubiquitin ligase activity, we asked if 
an ubiquitination step is required for the final clearance of 
impaired mitochondria. To test this, we immunostained parkin-
expressing cells with an antibody for polyubiquitin. The ubiquitin 
antibody reacted strongly with the majority of perinuclear   
mitochondrial aggregates, indicating that mitochondria are 
ubiquitinated (Fig. 3, A and B). Indeed, ubiquitinated protein 
Figure 2.  CCCP-induced parkin-mitochondrial aggregate formation is an intermediate step for mitophagy. (A) MEFs expressing WT GFP-parkin were 
treated with CCCP or CCCP and nocodazole (NOC, 10 µM) for 8, 16, and 24 h as indicated. Cells were immunostained with anti-Tom20 to visualize 
mitochondria. GFP-parkin–positive cells are marked by dotted lines. Arrows indicate parkin-positive mitochondria or mitochondrial aggregates. Bar, 25 µm. 
(B) The average percentages of cells with mitochondrial aggregates or without mitochondria from three independent experiments from A are presented with 
standard deviation as error bar. **, P < 0.01.675 Disease-causing mutations in Parkin impair mitophagy • Lee et al.
HDAC6, cortactin, and p62 are required 
for the clearance of impaired mitochondria
We next determined if HDAC6 and p62 are required for the 
clearance of dysfunctional mitochondria. Parkin failed to clear 
CCCP-treated mitochondria in HDAC6 knockout (KO) MEFs 
(Fig. 4 E) or p62 knockdown U2OS cells (Fig. S3). It is notable 
that large perinuclear mitochondrial aggregates did not form in 
HDAC6 KO MEFs, suggesting that HDAC6 is also required for 
the transport and concentration of damaged mitochondria. The 
parkin-CCCP–induced mitophagy can be effectively restored 
upon the reintroduction of wild-type HDAC6 (Fig. 4 E, bottom). 
et al., 2010). As E3 ligase–deficient parkin A240R and T415N 
mutants failed to complete mitophagy (Fig. 1), we asked if 
mitochondrial ubiquitination is involved in recruiting autoph-
agy machineries. As shown in Fig. 4, both p62 and HDAC6 
are prominently localized to ubiquitinated mitochondrial ag-
gregates in wild-type parkin-expressing cells. In contrast, the 
mitochondrial localization of p62 and HDAC6 is significantly   
less abundant in parkin A240R and T415N mutant-expressing 
cells. This result indicates that parkin-CCCP–dependent mito-
chondrial ubiquitination recruits p62 and HDAC6 to dam-
aged mitochondria.
Figure 3.  Parkin promotes mitochondrial ubiquitination. (A) MEFs were transfected with GFP wild-type (WT), A240R, and T415N mutant parkin followed 
by CCCP treatment for 8 h. Cells were immunostained with antibodies for cytochrome c (red) and ubiquitin (blue). Arrows indicate mitochondrial aggre-
gates. Bar, 10 µm. (B) The average percentages of ubiquitin-positive mitochondrial aggregates from three independent experiments from A are presented 
with standard deviation as error bar. (C and D) MEFs were transfected and treated with CCCP as described in A. Cells were subjected to the fractionation 
to isolate crude mitochondria. Cytoplasmic and mitochondrial fractions were subjected to immunoblotting analysis using antibodies for ubiquitin, parkin, 
cytochrome c, and cytosolic Hsp90.JCB • VOLUME 189 • NUMBER 4 • 2010   676
Figure 4.  Parkin-mediated ubiquitination recruits p62 and HDAC6. MEFs were transfected with WT, A240R, and T415N mutant GFP-parkin followed by 
CCCP treatment for 8 h. Cells were double immunostained with cytochrome c (red) and p62 antibody (blue) in A, and cytochrome c (red) and HDAC6 
antibody in C. Arrows indicate mitochondrial aggregates. (B and D) The average percentages of p62- or HDAC6-positive mitochondrial aggregates from 
three independent experiments are presented with standard deviation as error bar. (E) Wild-type and HDAC6 knockout (KO) MEFs were transfected with 
parkin-GFP or cotransfected with a Flag-tagged HDAC6 followed by CCCP treatment for 16 h as indicated. Cells are immunostained with Tom20 (red) and 
Flag (blue) antibodies. Bar, 25 µm. (F) Wild-type MEFs were transfected with control or HDAC6 siRNA and parkin-GFP, and treated with or without CCCP 
for 16 h. Cell lysates were subjected to immunoblotting analysis using antibodies for Tom20, parkin, HDAC6, and actin.677 Disease-causing mutations in Parkin impair mitophagy • Lee et al.
arrest mitophagy at distinct stages and demonstrate that associa-
tion and clearance of impaired mitochondria represent different 
activities of parkin. These findings allow the reconstruction of 
parkin-dependent mitophagy into temporal events consisting of 
marking the damaged mitochondria by parkin association, trans-
porting the “marked” mitochondria to form mito-aggresomes, 
and finally the clearance of concentrated mitochondria by ubiq-
uitin-mediated autophagy. Failure in any of these steps would 
abrogate mitophagy, resulting in toxicity emanating from dam-
aged mitochondria.
The physiological function of parkin E3 ligase activity 
has been elusive. Our results indicate that impaired mito-
chondria are substrates of parkin. Interestingly, parkin-mediated 
mitochondrial ubiquitination apparently is not obligatory for 
mito-aggresome formation (Fig. 3 A); however, ubiquitin-
negative mitochondria are not further processed and become 
prominently accumulated (Figs. 1 and 3). Therefore, parkin-
dependent ubiquitination appears to provide the signal for the final 
clearance of impaired mitochondria concentrated at the peri-
nuclear region. Our results indicate that mitochondrial ubiqui-
tination acts to recruit HDAC6 and p62, two ubiquitin-binding 
proteins required for efficient autophagy that targets protein aggre-
gates (Lee et al., 2010). Indeed, HDAC6- and p62-deficient 
cells are defective in parkin-dependent mitophagy (Fig. 4 and 
Fig. S3 B). Altogether, these results provide strong support that 
ubiquitin modification is a critical basis for the specific and effec-
tive clearance of damaged mitochondria by QC autophagy.
The  parkin-mediated  formation  of  CCCP-depolarized 
mitochondrial aggregate is intriguing, as this structure resembles 
the aggresome. Similar to the aggresome, the formation of mito-
chondrial aggregate (mito-aggresome) depends on microtubule 
dynein motors and HDAC6 (Figs. 2 A, 4 E, and S3 A). Interest-
ingly, a recent study found that PINK1 overexpression induced 
parkin association with mitochondria and also led to mito-
chondrial aggregate formation, although the significance of mito-
chondrial aggregates was not addressed (Vives-Bauza et al., 2010). 
To confirm the role of HDAC6 in mitophagy, we knocked 
down HDAC6 by specific siRNA in parkin-expressing cells 
and  determined  mitochondrial  Tom20  levels  by  immuno-
blotting after CCCP treatment. As shown in Fig. 4 G, Tom20 
levels were greatly reduced in control but not in HDAC6 knock-
down cells, demonstrating an important role for HDAC6 in 
parkin-mediated mitophagy.
We have shown that HDAC6 facilitates the clearance of 
protein aggregates by recruiting cortactin-dependent actin re-
modeling machinery, which promotes the fusion of autophago-
some and lysosome. To determine if cortactin is also required 
for impaired mitochondrion clearance, we knocked down cor-
tactin by siRNA and assessed parkin-dependent mitophagy. As 
shown in Fig. 5 A, inactivation of cortactin led to prominent 
accumulation of parkin-positive mitochondrial aggregates at 
the perinuclear region, indicative of a mitophagy failure. Indeed, 
immunoblotting analysis showed that cortactin knockdown, simi-
lar to HDAC6 inactivation, prevents the loss of mitochondrial 
markers induced by CCCP (Fig. 5 B). We conclude that, similar 
to protein aggregate processing, HDAC6, cortactin, and p62 are 
required for the clearance of damaged mitochondria.
In this study, we found that several disease-associated 
mutations located in different functional domains all abrogate 
the ability of parkin to clear impaired mitochondria, demon-
strating a tight link between parkin-dependent mitophagy and the 
suppression of Parkinsonism. Importantly, analyses of parkin 
mutants revealed distinct mitochondrial phenotypes, indicating 
a complex activity of parkin in mitophagy (Fig. 1). The phenotype 
of the R42P mutant indicates that the UBL domain is required 
for parkin recruitment to mitochondria (Fig. 1). The ubiquitin 
E3 ligase–deficient A240R and T415N mutants are capable of 
promoting mitochondrial aggregate formation, termed mito-
aggresomes,  but  cannot  promote  clearance  of  mitochondria 
(Figs. 1 and 3). In contrast, the R275W mutant can associate with 
depolarized mitochondria but is deficient in promoting mito-
aggresome formation. Thus, these disease-causing parkin mutants 
Figure 5.  Cortactin is required for parkin-CCCP–induced mitochondrial clearance. MEFs were transfected with control or cortactin RNAi and parkin-GFP, 
and incubated with or without CCCP for 16 h as indicated. (A) Cells were subjected to immunostaining with antibodies for Tom20 and parkin. Bar, 10 µm. 
(B) Cell lysates were subjected to immunoblotting with antibodies for Tom20, parkin, cortactin, and actin.JCB • VOLUME 189 • NUMBER 4 • 2010   678
Statistical analysis
A two-tailed Student’s t test was conducted for statistic analysis of quantita-
tive data.
Online supplemental material
Fig. S1. Endogenous parkin triggers mitophagy in SH-SYY5 neuroblastoma 
cells under CCCP treatment and paraquat treatment induces mito-aggregate.   
Fig. S2. Wild-type and mutant parkins are mainly localized in cytosol without   
CCCP treatment. Fig. S3. The formation of mitochondrial aggregate is   
inhibited by overexpressed dynamitin and requires p62. Online supple-
mental  material  is  available  at  http://www.jcb.org/cgi/content/full/jcb 
.201001039/DC1.
We thank Dr. M. Ehlers for reagents and A. Wagner for comments.
This  work  is  supported  by  a  National  Institutes  of  Health  grant 
(NS053825) to T.-P. Yao.
Submitted: 8 January 2010
Accepted: 16 April 2010
References
Abou-Sleiman, P.M., M.M. Muqit, and N.W. Wood. 2006. Expanding insights of 
mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci. 
7:207–219. doi:10.1038/nrn1868
Chung, K.K., Y. Zhang, K.L. Lim, Y. Tanaka, H. Huang, J. Gao, C.A. Ross, V.L. 
Dawson, and T.M. Dawson. 2001. Parkin ubiquitinates the alpha-synuclein-
interacting protein, synphilin-1: implications for Lewy-body formation in 
Parkinson disease. Nat. Med. 7:1144–1150. doi:10.1038/nm1001-1144
Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, 
X.F.  Wang,  and  T.P. Yao.  2002.  HDAC6  is  a  microtubule-associated 
deacetylase. Nature. 417:455–458. doi:10.1038/417455a
Iwata, A., B.E. Riley, J.A. Johnston, and R.R. Kopito. 2005. HDAC6 and micro-
tubules are required for autophagic degradation of aggregated huntingtin. 
J. Biol. Chem. 280:40282–40292. doi:10.1074/jbc.M508786200
Johnston, J.A., M.E. Illing, and R.R. Kopito. 2002. Cytoplasmic dynein/dynactin 
mediates the assembly of aggresomes. Cell Motil. Cytoskeleton. 53:26–
38. doi:10.1002/cm.10057
Kawaguchi, Y., J.J. Kovacs, A. McLaurin, J.M. Vance, A. Ito, and T.P. Yao. 2003. 
The deacetylase HDAC6 regulates aggresome formation and cell viability 
in response to misfolded protein stress. Cell. 115:727–738. doi:10.1016/ 
S0092-8674(03)00939-5
Lee, J.Y., H. Kim, C.H. Ryu, J.Y. Kim, B.H. Choi, Y. Lim, P.W. Huh, Y.H. Kim, 
K.H. Lee, T.Y. Jun, et al. 2004. Merlin, a tumor suppressor, interacts with 
transactivation-responsive RNA-binding protein and inhibits its oncogenic 
activity. J. Biol. Chem. 279:30265–30273. doi:10.1074/jbc.M312083200
Lee, J.Y., H. Koga, Y. Kawaguchi, W. Tang, E. Wong, Y.S. Gao, U.B. Pandey, S. 
Kaushik, E. Tresse, J. Lu, et al. 2010. HDAC6 controls autophagosome 
maturation  essential  for  ubiquitin-selective  quality-control  autophagy. 
EMBO J. 29:969–980. doi:10.1038/emboj.2009.405
Lim, K.L., K.C. Chew, J.M. Tan, C. Wang, K.K. Chung, Y. Zhang, Y. Tanaka, W. 
Smith, S. Engelender, C.A. Ross, et al. 2005. Parkin mediates nonclassi-
cal, proteasomal-independent ubiquitination of synphilin-1: implications 
for Lewy body formation. J. Neurosci. 25:2002–2009. doi:10.1523/ 
JNEUROSCI.4474-04.2005
Lücking, C.B., A. Dürr, V. Bonifati, J. Vaughan, G. De Michele, T. Gasser, B.S. 
Harhangi, G. Meco, P. Denèfle, N.W. Wood, et al; French Parkinson’s 
Disease  Genetics  Study  Group;  European  Consortium  on  Genetic 
Susceptibility in Parkinson’s Disease. 2000. Association between early-
onset Parkinson’s disease and mutations in the parkin gene. N. Engl. J. 
Med. 342:1560–1567. doi:10.1056/NEJM200005253422103
McNaught, K.S., P. Shashidharan, D.P. Perl, P. Jenner, and C.W. Olanow. 2002. 
Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16:2136–
2148. doi:10.1046/j.1460-9568.2002.02301.x
Mizushima, N., B. Levine, A.M. Cuervo, and D.J. Klionsky. 2008. Autophagy 
fights disease through cellular self-digestion. Nature. 451:1069–1075. 
doi:10.1038/nature06639
Narendra, D., A. Tanaka, D.F. Suen, and R.J. Youle. 2008. Parkin is recruited se-
lectively to impaired mitochondria and promotes their autophagy. J. Cell 
Biol. 183:795–803. doi:10.1083/jcb.200809125
Olzmann, J.A., L. Li, M.V. Chudaev, J. Chen, F.A. Perez, R.D. Palmiter, and L.S. 
Chin. 2007. Parkin-mediated K63-linked polyubiquitination targets mis-
folded DJ-1 to aggresomes via binding to HDAC6. J. Cell Biol. 178:1025–
1038. doi:10.1083/jcb.200611128
Pandey, U.B., Y. Batlevi, E.H. Baehrecke, and J.P. Taylor. 2007. HDAC6 at the 
intersection of autophagy, the ubiquitin-proteasome system and neuro-
degeneration. Autophagy. 3:643–645.
We found that mito-aggresome formation is required for efficient 
mitochondrial clearance (Fig. 2). We propose that impaired mito-
chondria under pathological conditions are concentrated by parkin- 
and HDAC6-dependent aggresomal pathway to the juxtanuclear 
region where they are cleared by QC autophagy. Indeed, paraquat, 
a mitochondrial complex I inhibitor linked to PD, could induce 
mito-aggresome formation (Fig. S1 C). Our study revealed that 
protein aggregates and impaired mitochondria are processed by 
a common pathway involving HDAC6- and parkin-dependent 
ubiquitin-selective autophagy and aggresomal machinery, thus 
providing a unifying model toward understanding the two most 
common pathological features in the pathogenesis of PD.
Materials and methods
Cell lines and plasmids
Immortalized wild-type and HDAC6 KO MEFs were obtained from E14.5 
wild-type and HDAC6 KO littermate embryos using 3T3 protocol as de-
scribed previously (Lee et al., 2010) and maintained in DME with 10% 
FBS. U2OS and SH-SYY5 cells were purchased from the American Type 
Culture Collection and maintained in DME (U2OS) and Ham’s F12/DME 
(SH-SYY5) with 10% FBS. All cell lines were cultured in 37°C with 5% CO2. 
GFP-tagged wild-type and mutant parkin expression plasmids were pro-
vided by Dr. Michael Ehlers (Duke University, Durham, NC).
Antibodies and reagents
Anti–mouse HDAC6 antibody was generated against aa 991–1149. The 
following antibodies/reagents were also used: anti-HDAC6 (H-300; Santa 
Cruz Biotechnology, Inc.), anti-ubiquitin (Enzo Life Sciences, Inc. and EMD), 
anti-p62 (Santa Cruz Biotechnology, Inc.), anti-mitochondrial Hsp70 (Thermo 
Fisher Scientific), anti-COX IV (Invitrogen), anti-cortactin (Millipore), anti-
cytochrome c (BD), and nocodazole (Sigma-Aldrich).
Immunofluorescence microscopy
Immunostaining was performed as described previously (Hubbert et al., 
2002; Lee et al., 2004). Cells were cultured on a glass cover slide for 1 d 
and transfected with wild-type or mutant Parkin expression plasmid. Cells 
were treated with the mitochondrial uncoupler CCCP at 25 µM for required 
amounts of time (8, 16, and 24 h). Cells were fixed in 4% paraformalde-
hyde made in phosphate-buffered saline (PBS) for 15 min at room tempera-
ture.  Cells  were  stained  with  the  following  primary  antibodies:  mouse 
monoclonal cytochrome c (BD), rabbit polyclonal Tom20 (Santa Cruz Bio-
technology, Inc.), rabbit polyclonal ubiquitin (Enzo Life Sciences, Inc.), rab-
bit  polyclonal  p62  (Santa  Cruz  Biotechnology,  Inc.),  rabbit  polyclonal 
HDAC6 (generated against aa 991–1149 of HDAC6); and with the fol-
lowing secondary antibodies: mouse and/or rabbit Alexa 488 (Invitrogen), 
rhodamine (Jackson ImmunoResearch Laboratories, Inc.), and Cy5 (Jackson 
ImmunoResearch Laboratories, Inc.). Samples are mounted with Anti-Fade 
Fluoromount  G  media  (SouthernBiotech)  for  imaging.  Images  were  ac-
quired by a spinning-disk confocal microscope (DMI6000C; Leica) at room 
temperature equipped with a charge-coupled device camera (ORCA ER; 
Hamamatsu Photonics), using 100x/1.4–0.70 NA oil (Plan Apochro-
mat; Leica) or 40x/1.25–0.75 oil NA (Plan NeoFluar; Leica) objectives. 
Images were acquired and processed with the Leica LAS AF program 
version 1.8.2.
Mitochondrial fractionation
Mitochondria purification was performed with a modified method from 
previous methods (Schwer et al., 2002). In brief, cells were homogenized 
in ice-cold buffer H (210 mM mannitol, 70 mM sucrose, 0.1 mM EGTA, 
and 2 mM Hepes-KOH, pH 7.5). Cell homogenates were incubated with 
anti-Tom20 immobilized magnetic beads for 2 h. Mitochondria were iso-
lated with Tom20 immobilized magnetic beads using magnetic field.
Western blotting
MEFs stably expressing GFP-Parkin were harvested. Samples were run on 
SDS-PAGE and immunoblotted with the following antibodies: polyclonal 
rabbit anti-Parkin (Invitrogen), rabbit anti-ubiquitin (Enzo Life Sciences, 
Inc.), rabbit anti-HDAC6 (generated against aa 991–1149 of HDAC6), 
rabbit anti-Tom20 (Santa Cruz Biotechnology, Inc.), and mouse anti-
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